APO Research
Talk to an analyst

APO RESEARCH · REPORT

Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Outlook and Growth Opportunities 2026

23 December 2025203 pages

Choose your research edition.

Industry ResearchPorcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Research Report 2026139 pages · $2,950 USDIndustry Growth & TrendsGlobal Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market include China Animal Husbandry Co., Ltd., Yongshun Biological, Tiankang, Zoetis, Ruipu Biological, Qilu Animal Health, Pulike Biological, Jinyu and Sinopharm Animal Health, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Segment by Company

China Animal Husbandry Co., Ltd.

Yongshun Biological

Tiankang

Zoetis

Ruipu Biological

Qilu Animal Health

Pulike Biological

Jinyu

Sinopharm Animal Health

Dahuanong

Boehringer Ingelheim

Phibro Animal Health

MSD Animal Health

Komipharm

Ceva

CAVAC

Bioveta

Agrovet

Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Segment by Type

Live vaccines

Inactivated vaccines

Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Segment by Application

Government bidding

Market sales

Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine industry.

Chapter 3: Detailed analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Trends Table 2. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Drivers Table 3. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Opportunities and Challenges Table 4. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Restraints Table 5. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue Share by Company (2021-2026) Table 7. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price (USD/unit) of Company (2021-2026) Table 10. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Company, Product Type & Application Table 13. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Live vaccines Table 18. Significant Companies of Inactivated vaccines Table 19. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Government bidding Table 30. Significant Companies of Market sales Table 31. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Application (2021-2026) & (k units) Table 33. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Application (2027-2032) & (k units) Table 34. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region (2027-2032) & (k units) Table 45. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Average Price (USD/unit) by Region (2021-2026) Table 52. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Average Price (USD/unit) by Region (2027-2032) Table 53. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (2021-2026) & (k units) Table 56. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Market Share by Country (2027-2032) Table 63. China Animal Husbandry Co., Ltd. Company Information Table 64. China Animal Husbandry Co., Ltd. Business Overview Table 65. China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 67. China Animal Husbandry Co., Ltd. Recent Development Table 68. Yongshun Biological Company Information Table 69. Yongshun Biological Business Overview Table 70. Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 72. Yongshun Biological Recent Development Table 73. Tiankang Company Information Table 74. Tiankang Business Overview Table 75. Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 77. Tiankang Recent Development Table 78. Zoetis Company Information Table 79. Zoetis Business Overview Table 80. Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 82. Zoetis Recent Development Table 83. Ruipu Biological Company Information Table 84. Ruipu Biological Business Overview Table 85. Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 87. Ruipu Biological Recent Development Table 88. Qilu Animal Health Company Information Table 89. Qilu Animal Health Business Overview Table 90. Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 92. Qilu Animal Health Recent Development Table 93. Pulike Biological Company Information Table 94. Pulike Biological Business Overview Table 95. Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 97. Pulike Biological Recent Development Table 98. Jinyu Company Information Table 99. Jinyu Business Overview Table 100. Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 102. Jinyu Recent Development Table 103. Sinopharm Animal Health Company Information Table 104. Sinopharm Animal Health Business Overview Table 105. Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 107. Sinopharm Animal Health Recent Development Table 108. Dahuanong Company Information Table 109. Dahuanong Business Overview Table 110. Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 112. Dahuanong Recent Development Table 113. Boehringer Ingelheim Company Information Table 114. Boehringer Ingelheim Business Overview Table 115. Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 117. Boehringer Ingelheim Recent Development Table 118. Phibro Animal Health Company Information Table 119. Phibro Animal Health Business Overview Table 120. Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 122. Phibro Animal Health Recent Development Table 123. MSD Animal Health Company Information Table 124. MSD Animal Health Business Overview Table 125. MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 127. MSD Animal Health Recent Development Table 128. Komipharm Company Information Table 129. Komipharm Business Overview Table 130. Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 132. Komipharm Recent Development Table 133. Ceva Company Information Table 134. Ceva Business Overview Table 135. Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 137. Ceva Recent Development Table 138. CAVAC Company Information Table 139. CAVAC Business Overview Table 140. CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 142. CAVAC Recent Development Table 143. Bioveta Company Information Table 144. Bioveta Business Overview Table 145. Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 147. Bioveta Recent Development Table 148. Agrovet Company Information Table 149. Agrovet Business Overview Table 150. Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio Table 152. Agrovet Recent Development Table 153. Key Raw Materials Table 154. Raw Materials Key Suppliers Table 155. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Distributors List Table 156. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Customers List Table 157. Research Programs/Design for This Report Table 158. Authors List of This Report Table 159. Secondary Sources Table 160. Primary Sources List of Figures Figure 1. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Image Figure 2. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales (2021-2032) & (k units) Figure 5. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Live vaccines Image Figure 10. Inactivated vaccines Image Figure 11. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type (2021-2032) Figure 17. Government bidding Image Figure 18. Market sales Image Figure 19. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Live vaccines
  • Inactivated vaccines
Applications
  • Government bidding
  • Market sales
Companies covered
  • China Animal Husbandry Co., Ltd.
  • Yongshun Biological
  • Tiankang
  • Zoetis
  • Ruipu Biological
  • Qilu Animal Health
  • Pulike Biological
  • Jinyu
  • Sinopharm Animal Health
  • Dahuanong
  • Boehringer Ingelheim
  • Phibro Animal Health
  • MSD Animal Health
  • Komipharm
  • Ceva
  • CAVAC
  • Bioveta
  • Agrovet

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Dynamics
  1. 2.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Trends
  2. 2.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Drivers
  3. 2.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Opportunities and Challenges
  4. 2.4 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Industry Restraints
3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market by Company
  1. 3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Company Product Type and Application
  8. 3.8 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market by Type
  1. 4.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Type Introduction
  2. 4.1.1 Live vaccines
  3. 4.1.2 Inactivated vaccines
  4. 4.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Type
  5. 4.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type
  9. 4.3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type (2021-2032)
5 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market by Application
  1. 5.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Application Introduction
  2. 5.1.1 Government bidding
  3. 5.1.2 Market sales
  4. 5.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Application
  5. 5.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application
  9. 5.3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application (2021-2032)
6 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Country, 2025 VS 2032
7 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 China Animal Husbandry Co., Ltd.
  2. 8.1.1 China Animal Husbandry Co., Ltd. Company Information
  3. 8.1.2 China Animal Husbandry Co., Ltd. Business Overview
  4. 8.1.3 China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 China Animal Husbandry Co., Ltd. Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  6. 8.1.5 China Animal Husbandry Co., Ltd. Recent Developments
  7. 8.2 Yongshun Biological
  8. 8.2.1 Yongshun Biological Company Information
  9. 8.2.2 Yongshun Biological Business Overview
  10. 8.2.3 Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Yongshun Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  12. 8.2.5 Yongshun Biological Recent Developments
  13. 8.3 Tiankang
  14. 8.3.1 Tiankang Company Information
  15. 8.3.2 Tiankang Business Overview
  16. 8.3.3 Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Tiankang Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  18. 8.3.5 Tiankang Recent Developments
  19. 8.4 Zoetis
  20. 8.4.1 Zoetis Company Information
  21. 8.4.2 Zoetis Business Overview
  22. 8.4.3 Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zoetis Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  24. 8.4.5 Zoetis Recent Developments
  25. 8.5 Ruipu Biological
  26. 8.5.1 Ruipu Biological Company Information
  27. 8.5.2 Ruipu Biological Business Overview
  28. 8.5.3 Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Ruipu Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  30. 8.5.5 Ruipu Biological Recent Developments
  31. 8.6 Qilu Animal Health
  32. 8.6.1 Qilu Animal Health Company Information
  33. 8.6.2 Qilu Animal Health Business Overview
  34. 8.6.3 Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Qilu Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  36. 8.6.5 Qilu Animal Health Recent Developments
  37. 8.7 Pulike Biological
  38. 8.7.1 Pulike Biological Company Information
  39. 8.7.2 Pulike Biological Business Overview
  40. 8.7.3 Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pulike Biological Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  42. 8.7.5 Pulike Biological Recent Developments
  43. 8.8 Jinyu
  44. 8.8.1 Jinyu Company Information
  45. 8.8.2 Jinyu Business Overview
  46. 8.8.3 Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Jinyu Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  48. 8.8.5 Jinyu Recent Developments
  49. 8.9 Sinopharm Animal Health
  50. 8.9.1 Sinopharm Animal Health Company Information
  51. 8.9.2 Sinopharm Animal Health Business Overview
  52. 8.9.3 Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sinopharm Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  54. 8.9.5 Sinopharm Animal Health Recent Developments
  55. 8.10 Dahuanong
  56. 8.10.1 Dahuanong Company Information
  57. 8.10.2 Dahuanong Business Overview
  58. 8.10.3 Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Dahuanong Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  60. 8.10.5 Dahuanong Recent Developments
  61. 8.11 Boehringer Ingelheim
  62. 8.11.1 Boehringer Ingelheim Company Information
  63. 8.11.2 Boehringer Ingelheim Business Overview
  64. 8.11.3 Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Boehringer Ingelheim Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  66. 8.11.5 Boehringer Ingelheim Recent Developments
  67. 8.12 Phibro Animal Health
  68. 8.12.1 Phibro Animal Health Company Information
  69. 8.12.2 Phibro Animal Health Business Overview
  70. 8.12.3 Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Phibro Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  72. 8.12.5 Phibro Animal Health Recent Developments
  73. 8.13 MSD Animal Health
  74. 8.13.1 MSD Animal Health Company Information
  75. 8.13.2 MSD Animal Health Business Overview
  76. 8.13.3 MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 MSD Animal Health Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  78. 8.13.5 MSD Animal Health Recent Developments
  79. 8.14 Komipharm
  80. 8.14.1 Komipharm Company Information
  81. 8.14.2 Komipharm Business Overview
  82. 8.14.3 Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Komipharm Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  84. 8.14.5 Komipharm Recent Developments
  85. 8.15 Ceva
  86. 8.15.1 Ceva Company Information
  87. 8.15.2 Ceva Business Overview
  88. 8.15.3 Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Ceva Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  90. 8.15.5 Ceva Recent Developments
  91. 8.16 CAVAC
  92. 8.16.1 CAVAC Company Information
  93. 8.16.2 CAVAC Business Overview
  94. 8.16.3 CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 CAVAC Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  96. 8.16.5 CAVAC Recent Developments
  97. 8.17 Bioveta
  98. 8.17.1 Bioveta Company Information
  99. 8.17.2 Bioveta Business Overview
  100. 8.17.3 Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Bioveta Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  102. 8.17.5 Bioveta Recent Developments
  103. 8.18 Agrovet
  104. 8.18.1 Agrovet Company Information
  105. 8.18.2 Agrovet Business Overview
  106. 8.18.3 Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Agrovet Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Product Portfolio
  108. 8.18.5 Agrovet Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Value Chain Analysis
  2. 9.1.1 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Mode & Process
  6. 9.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Distributors
  9. 9.2.3 Porcine Reproductive and Respiratory Syndrome (PRRS) Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst